On Friday, Inovio Pharmaceuticals Inc (NASDAQ: INO) was -10.59% drop from the session before settling in for the closing price of $4.77. A 52-week range for INO has been $4.20 – $14.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 60.80% over the past five years. When this article was written, the company’s average yearly earnings per share was at 25.81%. With a float of $25.88 million, this company’s outstanding shares have now reached $26.10 million.
Let’s look at the performance matrix of the company that is accounted for 122 employees. In terms of profitability, gross margin is -767.0%, operating margin of -13489577.67%, and the pretax margin is -12414736.82%.
Inovio Pharmaceuticals Inc (INO) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Inovio Pharmaceuticals Inc stocks. The insider ownership of Inovio Pharmaceuticals Inc is 0.85%, while institutional ownership is 33.05%.
Inovio Pharmaceuticals Inc (INO) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 25.81% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 41.50% during the next five years compared to 13.49% growth over the previous five years of trading.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Trading Performance Indicators
You can see what Inovio Pharmaceuticals Inc (INO) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 497.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.48, a number that is poised to hit -0.98 in the next quarter and is forecasted to reach -3.62 in one year’s time.
Technical Analysis of Inovio Pharmaceuticals Inc (INO)
Inovio Pharmaceuticals Inc (NASDAQ: INO) saw its 5-day average volume 0.57 million, a positive change from its year-to-date volume of 0.4 million. As of the previous 9 days, the stock’s Stochastic %D was 1.90%. Additionally, its Average True Range was 0.30.
During the past 100 days, Inovio Pharmaceuticals Inc’s (INO) raw stochastic average was set at 0.80%, which indicates a significant decrease from 4.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.93% in the past 14 days, which was lower than the 63.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.75, while its 200-day Moving Average is $8.67. Nevertheless, the first resistance level for the watch stands at $4.76 in the near term. At $5.25, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.53. If the price goes on to break the first support level at $3.99, it is likely to go to the next support level at $3.71. The third support level lies at $3.22 if the price breaches the second support level.
Inovio Pharmaceuticals Inc (NASDAQ: INO) Key Stats
There are 25,964K outstanding shares of the company, which has a market capitalization of 99.53 million. As of now, sales total 830 K while income totals -135,120 K. Its latest quarter income was 100 K while its last quarter net income were -32,240 K.
